StocksFundsScreenerSectorsWatchlists
MRTX

MRTX - Mirati Therapeutics Inc Stock Price, Fair Value and News

58.70USD Market Closed

Market Summary

MRTX
USD58.70
Market Closed

MRTX Stock Price

View Fullscreen

MRTX RSI Chart

MRTX Valuation

Market Cap

4.1B

Price/Earnings (Trailing)

-5.67

Price/Sales (Trailing)

107.82

EV/EBITDA

-5.27

Price/Free Cashflow

-6.91

MRTX Price/Sales (Trailing)

MRTX Profitability

EBT Margin

-1929.91%

Return on Equity

-76.69%

Return on Assets

-64.25%

Free Cashflow Yield

-14.47%

MRTX Fundamentals

MRTX Revenue

Revenue (TTM)

38.2M

Rev. Growth (Yr)

201.97%

Rev. Growth (Qtr)

19.8%

MRTX Earnings

Earnings (TTM)

-725.9M

Earnings Growth (Yr)

6.72%

Earnings Growth (Qtr)

8.48%

Breaking Down MRTX Revenue

Last 7 days

-0.8%

Last 30 days

1.8%

Last 90 days

5.6%

Trailing 12 Months

36.5%

How does MRTX drawdown profile look like?

MRTX Financial Health

Current Ratio

7.54

MRTX Investor Care

Shares Dilution (1Y)

21.81%

Diluted EPS (TTM)

-12.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202318.9M27.2M38.2M0
202267.0M48.8M30.6M12.4M
20210049.3M85.2M
20205.9M8.4M10.9M13.4M
20194.7M5.3M6.3M3.3M
20185.6M8.0M10.5M12.9M
20110003.1M

Tracking the Latest Insider Buys and Sells of Mirati Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 23, 2024
carter bruce l a
back to issuer
-
-
-17,273
-
Jan 23, 2024
sharp shalini
back to issuer
-
-
-16,222
-
Jan 23, 2024
hickey benjamin
back to issuer
-
-
-117,028
evp, chief commercial officer
Jan 23, 2024
johnson craig a
back to issuer
-
-
-17,273
-
Jan 23, 2024
baum charles m
back to issuer
-
-
-237,871
founder, president, and ceo
Jan 23, 2024
cherrington julie m
back to issuer
-
-
-11,252
-
Jan 23, 2024
sandler alan b.
back to issuer
-
-
-79,865
chief medical officer
Jan 23, 2024
boxer capital, llc
back to issuer
-
-
-3,201,440
-
Jan 23, 2024
martinez maria e
back to issuer
-
-
-17,273
-
Jan 23, 2024
boxer capital, llc
back to issuer
-
-
-3,658,100
-

1–10 of 50

Which funds bought or sold MRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
Allspring Global Investments Holdings, LLC
sold off
-100
-2,526
-
-%
Apr 17, 2024
Hennion & Walsh Asset Management, Inc.
sold off
-100
-1,400,070
-
-%
Apr 15, 2024
EXCHANGE TRADED CONCEPTS, LLC
sold off
-100
-249,218
-
-%
Apr 09, 2024
SYQUANT CAPITAL SAS
sold off
-100
-9,043,000
-
-%
Apr 05, 2024
CWM, LLC
sold off
-100
-70,000
-
-%
Mar 28, 2024
Newbridge Financial Services Group, Inc.
sold off
-100
-436
-
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
1.26
3,808
14,219
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
22,395,500
22,395,500
0.08%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-6.89
63,492,200
311,768,000
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
329
7,315,320
8,839,880
-%

1–10 of 41

Are Funds Buying or Selling MRTX?

Are funds buying MRTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRTX
No. of Funds

Unveiling Mirati Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
0.71%
5e+05
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
7.0%
4,886,840
SC 13G/A
Feb 14, 2024
rtw investments, lp
0%
0
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
0.0%
0
SC 13G
Feb 13, 2024
vanguard group inc
7.57%
5,306,693
SC 13G/A
Feb 09, 2024
morgan stanley
8.7%
6,079,302
SC 13G
Feb 09, 2024
morgan stanley
0.0%
0
SC 13G/A
Feb 08, 2024
wellington management group llp
0.00%
0
SC 13G/A
Jan 31, 2024
blackrock inc.
5.5%
3,866,202
SC 13G
Jan 25, 2024
boxer capital, llc
0%
0
SC 13D/A

Recent SEC filings of Mirati Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
15-12G
15-12G
Jan 31, 2024
SC 13G
Major Ownership Report

Peers (Alternatives to Mirati Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.7B
6.8B
-1.66% -28.18%
-8.22
5.66
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.2B
1.8B
-2.46% -28.84%
-41.3
9.94
76.23% 61.08%
16.7B
2.4B
4.57% -8.46%
99.75
6.91
15.42% 18.43%
11.8B
3.7B
-10.11% -29.11%
19.67
3.18
8.87% 75.42%
MID-CAP
5.7B
396.6M
-14.37% -42.33%
-10.84
14.45
425.83% 18.94%
4.4B
-
-13.59% 50.21%
-6.66
60.35
54.84% -34.79%
3.2B
270.6M
-13.81% -4.67%
-13.46
11.9
440.80% -27.84%
2.8B
726.4M
-9.91% -15.82%
-45.19
3.81
40.45% 71.62%
2.8B
240.7M
-20.67% -25.33%
-9.33
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-10.64% -8.42%
24.94
4.47
85.90% -14.05%
558.4M
983.7M
-17.39% -51.52%
-1.02
0.57
-50.36% 17.16%
409.4M
881.7K
-0.38% 387.14%
-9.18
466.16
-77.61% -5.33%
226.2M
4.9M
-10.29% -2.81%
-1.67
46.49
-54.97% 51.71%
6.0M
2.1M
59.81% 33.59%
-0.22
2.14
-13.45% 66.37%

Mirati Therapeutics Inc News

Latest updates
Marketscreener.com2 months ago
Investor's Business Daily6 months ago

Mirati Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue19.8%16,400,00013,690,0007,167,000934,0005,431,0005,362,0002,830,500299,00071,793,0001,708,00011,424,0007,791,3334,158,667526,000988,000577,0001,244,0003,459,000--9,467,000
Operating Expenses-6.2%188,454,000200,960,000200,990,000212,657,000191,874,000182,567,000184,927,000197,374,000151,292,000108,043,000100,102,00084,862,00089,754,00075,173,00058,047,00048,218,00044,002,00033,131,00028,939,00028,670,00024,813,000
  S&GA Expenses-4.6%72,001,00075,490,00073,490,00070,821,00060,798,00054,228,00053,951,00043,535,00035,183,00025,338,00020,249,00019,779,00018,046,00012,232,50010,685,0009,894,0009,762,0006,373,0005,313,0004,841,0005,154,000
  R&D Expenses-7.6%114,766,000124,187,000126,683,000141,236,000131,076,000128,339,000130,976,000153,839,000116,109,00082,705,00079,853,00065,083,00071,708,00062,940,50047,362,00038,324,00034,240,00026,758,00023,626,00023,829,00019,659,000
EBITDA Margin29.1%-19.19-27.06-39.01-59.30-21.06-13.63-10.08-8.00-6.21-26.67-----------
Income Taxes----254,000254,000---3,299,000------------
Earnings Before Taxes-Infinity%-161,904,000---202,221,000-173,307,000---199,620,000-76,755,000-101,087,000-87,336,000----------
EBT Margin29.0%-19.30-27.20-39.18-59.53-21.15-13.69-10.12-8.02-6.23-26.72-----------
Net Income8.5%-161,904,000-176,913,000-184,586,000-202,475,000-173,561,000-176,445,000-188,386,000-199,620,000-80,054,000-101,087,000-87,336,000-82,859,000-86,655,000-72,376,000-54,273,000-45,695,000-40,912,000-28,272,000-27,568,000-27,869,000-14,709,000
Net Income Margin29.8%-19.01-27.09-39.01-59.57-26.98-15.25-11.10-8.07-8.42-26.72-----------
Free Cashflow-8.8%-143,749,000-132,122,000-190,451,000-129,610,000-139,049,000-145,153,000-161,609,000-140,634,000-49,041,000-77,927,000-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets23.5%1,1309151,0341,2031,3031,2801,4211,5891,2531,3561,3811,476620664713432471501309228248
  Current Assets26.5%1,0368199391,1091,2261,2031,3431,5081,1721,2781,3041,404595654705424465496306227246
    Cash Equivalents99.2%25913024223529926630541424328133088613113220547.0092.0025275.0033.00117
  Inventory133.2%20.009.004.003.00-----------------
  Net PPE-4.9%16.0017.0017.0018.0018.0017.0017.0016.0014.0012.009.008.006.003.002.002.001.000.000.000.000.00
Liabilities-1.5%18318617120617416817219216922712111569.0059.0057.0050.0036.0029.0026.0027.0023.00
  Current Liabilities-1.9%13714012515912711912414412218177.0071.0067.0058.0056.0049.0035.0028.0025.0026.0022.00
Shareholder's Equity29.8%9467298639971,1291,1121,2491,3971,0841,1291,2591,361551605656382434472284202225
  Retained Earnings-5.8%-2,976-2,814-2,637-2,452-2,250-2,076-1,900-1,712-1,512-1,432-1,265-1,130-1,029-941-858-772-699-645-599-559-530
  Additional Paid-In Capital10.7%3,9243,5453,5023,4533,3863,1853,1453,1002,5872,5522,5162,4811,5701,5351,5051,1451,1241,108874751746
Shares Outstanding20.2%70.0058.0058.0058.0056.0056.0055.0055.0052.0051.0051.0045.00---------
Float------3,700---7,400---4,433---2,907---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-9.4%-143,713-131,400-190,182-128,800-137,809-143,492-160,469-137,985-47,032-93,367-110,416-76,421-76,763-59,343-59,004-41,902-32,874-38,468-34,482-20,795-20,172
  Share Based Compensation13.1%44,55339,39946,96161,60742,99238,68442,90533,87826,93327,96924,72221,74321,75020,78721,56716,71115,10612,58911,1314,2624,058
Cashflow From Investing-500.4%-62,19415,532195,15159,29713,945103,00649,555-170,83870436,761-455,528-59,34064,157-22,447-122,227-6,939-128,066-5,927-35,208-63,68328,762
Cashflow From Financing8609.3%334,7003,8431,7275,920157,1051,3922,527479,2828,2327,8239,885889,88912,3519,273339,2013,4731,072221,882111,6014622,157

MRTX Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue$ 16,400$ 5,431$ 37,257$ 11,502
Revenue    
Total revenue16,4005,43137,25711,502
Operating expenses    
Cost of product revenue1,42803,0110
Cost of product revenue - intangible asset amortization25907760
Research and development114,766131,076365,636390,391
Selling, general and administrative72,00160,798220,981168,977
Total operating expenses188,454191,874590,404559,368
Loss from operations(172,054)(186,443)(553,147)(547,866)
Other income, net10,15013,13629,7449,728
Loss before income taxes(161,904)(173,307)(523,403)(538,138)
Income tax expense02540254
Net loss(161,904)(173,561)(523,403)(538,392)
Unrealized gain (loss) on available-for-sale investments106(1)2,175(5,712)
Foreign currency translation adjustment59(9,485)(6)(9,485)
Comprehensive loss$ (161,739)$ (183,047)$ (521,234)$ (553,589)
Basic net loss per share (USD per share)$ (2.49)$ (3.09)$ (8.66)$ (9.66)
Diluted net loss per share (USD per share)$ (2.49)$ (3.09)$ (8.66)$ (9.66)
Weighted average common shares outstanding, basic (shares)64,993,07956,219,41660,419,75555,747,205
Weighted average common shares outstanding, diluted (shares)64,993,07956,219,41660,419,75555,747,205
Product Revenue    
Total revenue$ 16,400$ 0$ 36,056$ 0
Revenue    
Total revenue16,400036,0560
License and Collaboration Revenue    
Total revenue05,4311,20111,502
Revenue    
Total revenue$ 0$ 5,431$ 1,201$ 11,502

MRTX Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 258,718$ 235,260
Short-term investments717,716848,577
Accounts receivable, net14,651865
Inventory20,1563,020
Other current assets24,83921,239
Total current assets1,036,0801,108,961
Property and equipment, net16,04617,540
Intangible asset, net14,13814,914
Long-term investment3,5593,465
Right-of-use asset35,06636,122
Other long-term assets24,81921,645
Total assets1,129,7081,202,647
Current liabilities  
Accounts payable37,96138,861
Accrued liabilities99,418120,587
Total current liabilities137,379159,448
Lease liability42,20343,661
Other liabilities3,6613,022
Total liabilities183,243206,131
Commitments and contingencies (see Note 11)
Shareholders' equity  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both September 30, 2023 and December 31, 202200
Common stock, $0.001 par value; 100,000,000 authorized; 70,111,309 and 57,854,559 issued and outstanding at September 30, 2023 and December 31, 2022, respectively7058
Additional paid-in capital3,924,2373,453,066
Accumulated other comprehensive loss(1,550)(3,719)
Accumulated deficit(2,976,292)(2,452,889)
Total shareholders' equity946,465996,516
Total liabilities and shareholders' equity$ 1,129,708$ 1,202,647
MRTX
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
 CEO
 WEBSITEmirati.com
 INDUSTRYBiotechnology
 EMPLOYEES587

Mirati Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Mirati Therapeutics Inc? What does MRTX stand for in stocks?

MRTX is the stock ticker symbol of Mirati Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirati Therapeutics Inc (MRTX)?

As of Tue Jan 23 2024, market cap of Mirati Therapeutics Inc is 4.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRTX stock?

You can check MRTX's fair value in chart for subscribers.

What is the fair value of MRTX stock?

You can check MRTX's fair value in chart for subscribers. The fair value of Mirati Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mirati Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mirati Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRTX is over valued or under valued. Whether Mirati Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mirati Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRTX.

What is Mirati Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jan 23 2024, MRTX's PE ratio (Price to Earnings) is -5.67 and Price to Sales (PS) ratio is 107.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Mirati Therapeutics Inc's stock?

In the past 10 years, Mirati Therapeutics Inc has provided 0.103 (multiply by 100 for percentage) rate of return.